BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thuss-Patience PC, Hofheinz RD, Arnold D, Florschütz A, Daum S, Kretzschmar A, Mantovani-Löffler L, Bichev D, Breithaupt K, Kneba M. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Ann Oncol. 2012;23:2827-2834. [PMID: 22734012 DOI: 10.1093/annonc/mds129] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Xing Y, Zhang Z, Ding Z, Song W, Li T. Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: case report and literature review.. [DOI: 10.21203/rs.3.rs-2387247/v1] [Reference Citation Analysis]
2 Chidambaram S, Sounderajah V, Maynard N, Owen R, Markar SR. Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus 2023;36. [PMID: 36151055 DOI: 10.1093/dote/doac058] [Reference Citation Analysis]
3 Lorusso A, Bichev D, Högner A, Bartels P, Ballhausen A, Treese C, Biebl M, Thuss-Patience P. Prognostic Relevance of Weight and Weight Loss during Multimodal Therapy for Oesophagogastric Tumours. Curr Oncol 2022;29:2706-19. [PMID: 35448195 DOI: 10.3390/curroncol29040221] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tsvetkova D, Ivanova S. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules 2022;27:2466. [PMID: 35458666 DOI: 10.3390/molecules27082466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Ballhausen A, Bartels P, Iacovella I, Hoegner A, Lorusso A, Bichev D, Daum S, Thuss-patience P. Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy. Current Oncology 2022;29:1983-96. [DOI: 10.3390/curroncol29030161] [Reference Citation Analysis]
6 Lorenzen S, Stocker G, Möhler M, Götze TO, Stein A, Gökkurt E, Haag GM, Albatran S, Hofheinz R, Homann N, Schmalenberg H, Stahl MK, Heinrich K, Mönig S, Thuss-patience P. Studien der Arbeitsgruppe Magen-Ösophagus-Tumoren der Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologe 2022;28:23-29. [DOI: 10.1007/s00761-021-01087-3] [Reference Citation Analysis]
7 Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract 2021;2021:5590626. [PMID: 34335737 DOI: 10.1155/2021/5590626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bartels P, Thuss-patience P. Inductive Preoperative Chemotherapy for Peritoneal Metastases of Tumors of the Upper GI Tract. Peritoneal Tumors and Metastases 2021. [DOI: 10.1007/978-3-030-62640-2_7] [Reference Citation Analysis]
10 Glatz T, Verst R, Kuvendjiska J, Bronsert P, Becker H, Hoeppner J, Kulemann B. Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials. J Clin Med 2020;9:E2654. [PMID: 32824326 DOI: 10.3390/jcm9082654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Sisic L, Blank S, Nienhüser H, Haag GM, Jäger D, Bruckner T, Ott K, Schmidt T, Ulrich A. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma. Surgical Oncology 2020;33:177-88. [DOI: 10.1016/j.suronc.2017.06.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
12 Li Y, Wang HC, Wang JS, Sun B, Li LP. Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer. FEBS Open Bio 2020;10:1149-61. [PMID: 32306562 DOI: 10.1002/2211-5463.12864] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MC. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open 2020;3:e1921290. [PMID: 32058557 DOI: 10.1001/jamanetworkopen.2019.21290] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
14 Uson Junior PLS, Santos VM, Bugano DDG, Victor EDS, Rother ET, Maluf FC. Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Sci Rep 2019;9:15806. [PMID: 31676841 DOI: 10.1038/s41598-019-52334-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Arai H, Sunakawa Y, Nakajima TE. Co-operative groups in the development of chemotherapy for gastric cancer. Jpn J Clin Oncol 2019;49:210-27. [PMID: 30508188 DOI: 10.1093/jjco/hyy176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Xu J, Li X, Lv X. Effect of oxaliplatin combined with 5-fluorouracil on treatment efficacy of radiotherapy in the treatment of elderly patients with rectal cancer. Exp Ther Med 2019;17:1517-22. [PMID: 30783416 DOI: 10.3892/etm.2018.7119] [Reference Citation Analysis]
17 Guo Y, Tang J, Huang XE, Cao J. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study. Medicine (Baltimore) 2019;98:e13908. [PMID: 30732125 DOI: 10.1097/MD.0000000000013908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
18 Tin AW, Smith E, Hepworth R, Walker J, Wilson D, Wadd N. Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. J Geriatr Oncol 2018;9:569-74. [PMID: 29884598 DOI: 10.1016/j.jgo.2018.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Thuss-patience P. Induktive präoperative Chemotherapie bei peritonealen Metastasen von Tumoren des oberen GI-Trakts. Peritoneale Tumoren und Metastasen 2018. [DOI: 10.1007/978-3-662-54500-3_7] [Reference Citation Analysis]
20 Caster JM, Tepper JE. Gastric Cancer (Siewert Type III). Practical Guides in Radiation Oncology 2018. [DOI: 10.1007/978-3-319-64900-9_3] [Reference Citation Analysis]
21 Struecker B, Andreou A, Chopra S, Heilmann AC, Spenke J, Denecke C, Sauer IM, Bahra M, Pratschke J, Biebl M. Evaluation of Anastomotic Leak after Esophagectomy for Esophageal Cancer: Typical Time Point of Occurrence, Mode of Diagnosis, Value of Routine Radiocontrast Agent Studies and Therapeutic Options. Dig Surg 2018;35:419-26. [PMID: 29131024 DOI: 10.1159/000480357] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
22 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Struecker B, Chopra S, Heilmann AC, Spenke J, Denecke C, Sauer IM, Bahra M, Pratschke J, Andreou A, Biebl M. Routine Radiologic Contrast Agent Examination After Gastrectomy for Gastric Cancer Is Not Useful. J Gastrointest Surg 2017;21:801-6. [PMID: 28205124 DOI: 10.1007/s11605-017-3384-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fernandez E, Cacheux W, Frossard JL, Koessler T, Abou M, Moniez M, Huber O, Puppa G, Roth A. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Dig Liver Dis 2017;49:552-6. [PMID: 28179095 DOI: 10.1016/j.dld.2016.12.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Habermehl D, Münch S. Neoadjuvant chemoradiation is highly effective and leads to high R0 resection rates and higher pCR rates than perioperative chemotherapy protocols with a comparable impact on distant metastasis. J Surg Oncol 2017;115:501-503. [DOI: 10.1002/jso.24531] [Reference Citation Analysis]
26 Cox SJ, O'Cathail SM, Coles B, Crosby T, Mukherjee S. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 2017;19:7. [PMID: 28213876 DOI: 10.1007/s11912-017-0559-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Chen L, Malhotra A. Combination Approach: the Future of the War Against Cancer. Cell Biochem Biophys 2015;72:637-41. [PMID: 25638344 DOI: 10.1007/s12013-015-0549-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
29 Kim S, Paget-bailly S, Messager M, Nguyen T, Mathieu P, Lamfichekh N, Fein F, Fratté S, Cléau D, Lakkis Z, Jary M, Sakek N, Jacquin M, Foubert A, Bonnetain F, Mariette C, Fiteni F, Borg C. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. European Journal of Surgical Oncology (EJSO) 2017;43:218-25. [DOI: 10.1016/j.ejso.2016.06.395] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
30 Zongo N, Halim BA, Edgar O, Carine BS, Maurice Z, Gilbert B, Adama S, Mélanie LO, Simon TS, Dem A. Gastric Adenocarcinoma Treatment in Africa: Surgery Alone or Perioperative Chemotherapy? JCT 2017;08:653-662. [DOI: 10.4236/jct.2017.87056] [Reference Citation Analysis]
31 Treese C, Daum S. Perioperative Systemtherapie bei Magen- und Kardiakarzinom. Moderne Chirurgie des Magen- und Kardiakarzinoms 2017. [DOI: 10.1007/978-3-662-53188-4_9] [Reference Citation Analysis]
32 Mary F, Zaanan A, Boige V, Artru P, Samalin E, Coriat R, Bachet JB, Boubaya M, Benallaoua M, Tougeron D, Afchain P, Locher C, Baumgaertner I, Lecaille C, des Guetz G, Aparicio T; AGEO (Association des Gastro-Entérologues Oncologues). Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. Dig Liver Dis 2016;48:1498-502. [PMID: 27623185 DOI: 10.1016/j.dld.2016.07.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
33 Al-sukhni E, Gabriel E, Attwood K, Kukar M, Nurkin SJ, Hochwald SN. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. Journal of the American College of Surgeons 2016;223:784-792.e1. [DOI: 10.1016/j.jamcollsurg.2016.09.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
34 Dassen AE, Bernards N, Lemmens VE, Wouw YAV, Bosscha K, Creemers GJ, Pruijt HJ. Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer. World J Gastrointest Surg 2016; 8(10): 706-712 [PMID: 27830043 DOI: 10.4240/wjgs.v8.i10.706] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697-708. [PMID: 27776843 DOI: 10.1016/S1470-2045(16)30531-9] [Cited by in Crossref: 344] [Cited by in F6Publishing: 382] [Article Influence: 49.1] [Reference Citation Analysis]
36 Fiteni F, Paget-Bailly S, Messager M, N'Guyen T, Lakkis Z, Mathieu P, Lamfichekh N, Picard A, Benzidane B, Cléau D. Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. Cancer Med. 2016;5:3085-3093. [PMID: 27726290 DOI: 10.1002/cam4.885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
37 Andreou A, Biebl M, Dadras M, Struecker B, Sauer IM, Thuss-Patience PC, Chopra S, Fikatas P, Bahra M, Seehofer D, Pratschke J, Schmidt SC. Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer. Surgery 2016;160:191-203. [PMID: 27067160 DOI: 10.1016/j.surg.2016.02.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
38 Glatz T, Bronsert P, Schäfer M, Kulemann B, Marjanovic G, Sick O, Hopt U, Zirlik K, Makowiec F, Hoeppner J. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. European Journal of Surgical Oncology (EJSO) 2015;41:1300-7. [DOI: 10.1016/j.ejso.2015.07.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
39 Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833-42. [PMID: 25214034 DOI: 10.1007/s10120-014-0423-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
40 Sylvie L, Silvia S, Salah-eddin A, Markus F, Florian L, Peter T, Bernhard H, Martin A, Alexander N. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer. European Journal of Cancer 2015;51:1918-26. [DOI: 10.1016/j.ejca.2015.07.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
41 Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C. The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. J Hematol Oncol. 2015;8:52. [PMID: 25976888 DOI: 10.1186/s13045-015-0148-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
42 Liu L, Yu H, Huang L, Shao F, Bai J, Lou D, Chen F. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther 2015;8:921-8. [PMID: 25960663 DOI: 10.2147/OTT.S82365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
43 Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer 2015;18:314-25. [PMID: 24722800 DOI: 10.1007/s10120-014-0367-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
44 Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015;137:678-685. [PMID: 25530271 DOI: 10.1002/ijc.29403] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 7.5] [Reference Citation Analysis]
45 Andreou A, Viganò L, Zimmitti G, Seehofer D, Dreyer M, Pascher A, Bahra M, Schoening W, Schmitz V, Thuss-Patience PC, Denecke T, Puhl G, Vauthey JN, Neuhaus P, Capussotti L, Pratschke J, Schmidt SC. Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer. J Gastrointest Surg 2014;18:1974-86. [PMID: 25159501 DOI: 10.1007/s11605-014-2623-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
46 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
47 Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemother Pharmacol 2014;74:1139-47. [DOI: 10.1007/s00280-014-2586-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
48 Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemother Pharmacol. 2014;74:141-150. [PMID: 24824852 DOI: 10.1007/s00280-014-2482-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
49 Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. Acta Oncol 2014;53:392-8. [PMID: 24024696 DOI: 10.3109/0284186X.2013.833346] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
50 Popa EC, Shah MA. Capecitabine in the treatment of esophageal and gastric cancers. Expert Opinion on Investigational Drugs 2013;22:1645-57. [DOI: 10.1517/13543784.2013.842974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
51 Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219-3225. [PMID: 23918952 DOI: 10.1200/jco.2013.48.8585] [Cited by in Crossref: 316] [Cited by in F6Publishing: 385] [Article Influence: 31.6] [Reference Citation Analysis]
52 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
53 Thuss-patience P, Kutup A, Eble M. Adenokarzinome des Magens und gastroösophagealen Übergangs. Onkologe 2013;19:371-379. [DOI: 10.1007/s00761-012-2417-5] [Reference Citation Analysis]
54 Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013;24:2068-2073. [PMID: 23592699 DOI: 10.1093/annonc/mdt141] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
55 Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108:519-526. [PMID: 23322206 DOI: 10.1038/bjc.2012.588] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
56 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]